

**Question for written answer E-000104/2015
to the Commission**

Rule 130

José Blanco López (S&D)

Subject: Treatment of hepatitis C in the EU

Following my previous question E-006996/2014 on access in the EU to new drugs for hepatitis C, I should like to know whether the Commission has, as mentioned in its answer, facilitated the exchange of information and cooperation among Member States on this matter?

I should also like clarification as to whether Spain has asked the Commission for help to improve the exchange of information among Member States on their pricing policies with a view to making medicines more accessible?

Lastly, can the Commission confirm whether it has, as mentioned in its answer to my previous question, explored the possibility of using the joint procurement mechanism to secure more advantageous prices from the pharmaceutical industry?